MaaT microbiota drug shows survival advantage in GvHD April 17, 2024 AutoBot News 0 MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).